Literature DB >> 17324248

Piloerection induced by replacing fluvoxamine with milnacipran.

Satoko Hori1, Nobuko Matsuo, Akiko Yamamoto, Tomomi Hazui, Hiromi Yagi, Marumi Nakano, Yuka Suzuki, Akiko Miki, Hisakazu Ohtani, Yasufumi Sawada.   

Abstract

AIMS: To present a case of piloerection after replacing fluvoxamine maleate with milnacipran hydrochloride, and to analyse this effect based on receptor occupancy theory.
METHODS: A 40-year-old female with a 3-year history of panic disorder was prescribed fluvoxamine 50 mg day(-1) in addition to clorazepate dipotassium and sulpiride. Depression was not improved and she complained of fatigue, lack of energy and drowsiness. These symptoms worsened within a few days of an increase in the dose of fluvoxamine to 50 mg twice daily. Since an interaction between fluvoxamine and tizanidine, prescribed by another clinic, was suspected, fluvoxamine was replaced with milnacipran 50 mg day(-1). Although her drowsiness improved, she complained of piloerection throughout her body. This symptom gradually abated within a week and when the dosage of milnacipran was increased to 100 mg day(-1) at 2 months, no further piloerection occurred. We calculated the changes in alpha(1)-adrenoceptor occupancy by endogenous norepinephrine during treatment with the usual doses of milnacipran, fluvoxamine and imipramine by using pharmacokinetic and pharmacodynamic parameters obtained from the literature.
RESULTS: The ratios of alpha(1)-adrenoceptor occupancy by endogenous norepinephrine during the treatment with milnacipran, fluvoxamine and imipramine to that without drug were estimated to be 7.13, 1.00 and 4.12, respectively. The alpha(1)-adrenoceptor occupancy by endogenous norepinephrine was increased in a dose-dependent manner by milnacipran, whereas fluvoxamine had essentially no effect.
CONCLUSIONS: The piloerection observed after the replacement of fluvoxamine with milnacipran in this patient appears to have been due to an increase in the alpha(1)-adrenoceptor occupancy by endogenous norepinephrine induced by milnacipran.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17324248      PMCID: PMC2000592          DOI: 10.1111/j.1365-2125.2006.02838.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  21 in total

1.  Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

Authors:  I M Anderson
Journal:  J Affect Disord       Date:  2000-04       Impact factor: 4.839

2.  Elevation of blood pressure induced by high-dose milnacipran.

Authors:  Keizo Yoshida; Hisashi Higuchi; Hitoshi Takahashi; Tetsuo Shimizu
Journal:  Hum Psychopharmacol       Date:  2002-12       Impact factor: 1.672

Review 3.  Autonomic innervation of canine urinary bladder. Cholinergic and adrenergic contributions and interaction of sympathetic and parasympathetic nervous systems in bladder function.

Authors:  D M Raezer; A J Wein; D Jacobowitz; J N Corriere
Journal:  Urology       Date:  1973-09       Impact factor: 2.649

4.  Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro.

Authors:  E Richelson; A Nelson
Journal:  J Pharmacol Exp Ther       Date:  1984-07       Impact factor: 4.030

5.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

6.  Novel human alpha1a-adrenoceptor single nucleotide polymorphisms alter receptor pharmacology and biological function.

Authors:  Beilei Lei; Daniel P Morris; Michael P Smith; Laura P Svetkey; Mark F Newman; Jerome I Rotter; Thomas A Buchanan; Stephen M Beckstrom-Sternberg; Eric D Green; Debra A Schwinn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-03-10       Impact factor: 3.000

7.  Differences in the cellular localization and agonist-mediated internalization properties of the alpha(1)-adrenoceptor subtypes.

Authors:  Dan Chalothorn; Dan F McCune; Stephanie E Edelmann; Mary L García-Cazarín; Gozoh Tsujimoto; Michael T Piascik
Journal:  Mol Pharmacol       Date:  2002-05       Impact factor: 4.436

8.  Actions of tizanidine on alpha 1-and alpha 2-adrenoceptors in the peripheral tissues.

Authors:  I Takayanagi; F Konno; C Ishii; T Takemasa; Y Yanagida; M Shimizu; H Mori; H Sugane
Journal:  Gen Pharmacol       Date:  1984

9.  Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro.

Authors:  Marika T Granfors; Janne T Backman; Jouko Laitila; Pertti J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2004-03       Impact factor: 4.335

10.  Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction.

Authors:  Marika T Granfors; Janne T Backman; Mikko Neuvonen; Jouni Ahonen; Pertti J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  2004-04       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.